Literature DB >> 14760038

The value of urine screening in a young adult population.

Peter S Topham1, Ashok Jethwa, Maggie Watkins, Yvonne Rees, John Feehally.   

Abstract

BACKGROUND: GPs in England and Wales are required to perform screening urinalysis on all newly registered patients. The value of this practice, however, is unclear.
OBJECTIVE: The purpose of this study was to identify the prevalence of persistent urine abnormalities and to establish the added value of screening for both haematuria and proteinuria in a large cohort of young adults in the UK.
METHODS: Urine screening was carried out in a cohort of young adults in a student health centre and a university hospital nephrology unit in a large British city. University students enrolling for health screening in a university health centre over a 2-year period were tested for haematuria and/or proteinuria by dipstick urinalysis. Subjects with persistent urine abnormalities were evaluated for the presence of significant renal tract pathology.
RESULTS: Of 3808 students screened, 3570 provided an initial urine sample; 220 were abnormal. Of these, 38 (1% of original cohort) had persistent abnormalities (haematuria, 14; proteinuria, 16; both, eight). Subjects with isolated haematuria or proteinuria did not have significant pathology. In contrast, all the students with both haematuria and proteinuria had identifiable renal disease.
CONCLUSIONS: Our findings do not support the value of routine screening for proteinuria or haematuria in young adults. However, the combination of haematuria and proteinuria is a powerful predictor for parenchymal renal disease. Thus, if proteinuria is detected, further testing for haematuria should be performed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14760038     DOI: 10.1093/fampra/cmh105

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  6 in total

Review 1.  Best practice in primary care pathology: review 2.

Authors:  W S Smellie; J O Forth; C A M McNulty; L Hirschowitz; D Lilic; R Gosling; D Bareford; E Logan; K G Kerr; G P Spickett; J Hoffman; A Galloway; C A Bloxham
Journal:  J Clin Pathol       Date:  2006-02       Impact factor: 3.411

2.  Variation in the intensity of hematuria evaluation: a target for primary care quality improvement.

Authors:  David F Friedlander; Matthew J Resnick; Chaochen You; Jeffrey Bassett; Vidhush Yarlagadda; David F Penson; Daniel A Barocas
Journal:  Am J Med       Date:  2014-01-28       Impact factor: 4.965

Review 3.  [Microscopic hematuria : Reasonable and risk-adapted diagnostic evaluation].

Authors:  N Löbig; F Wezel; T Martini; B Schröppel; C Bolenz
Journal:  Urologe A       Date:  2017-09       Impact factor: 0.639

4.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

5.  Renal biopsy findings and clinical indicators of patients with hematuria without overt proteinuria.

Authors:  Yoshie Hoshino; Toshie Kaga; Yasutomo Abe; Mariko Endo; Sachiko Wakai; Ken Tsuchiya; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2015-02-13       Impact factor: 2.801

6.  Health assessment of French university students and risk factors associated with mental health disorders.

Authors:  Antoine Tran; Laurie Tran; Nicolas Geghre; David Darmon; Marion Rampal; Diane Brandone; Jean-Michel Gozzo; Hervé Haas; Karine Rebouillat-Savy; Hervé Caci; Paul Avillach
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.